UF PSMA Study Examines Highly Personalized Approach for Managing Advanced Prostate Cancer
In collaboration with Novartis, the UF Health Radiation Oncology and Genitourinary Oncology teams will begin screening eligible patients for the PSMAfore trial, which examines a new highly targeted, systemic radiopharmaceutical therapy for men with castrate-resistant prostate cancer. Men with metastatic prostate…